Abstract
Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease. It has one of the strongest cumulative evidence supporting its use in colorectal cancer (CRC) chemoprevention. Epidemiological, clinical, and observational studies have demonstrated that aspirin and non-steroidal antiinflammatory drugs (NSAIDs), including COX-2 inhibitors, can protect against CRC and significantly reduce its incidence. Moreover, prospective randomized controlled trials of colorectal polyp recurrence and in patients with hereditary CRC syndromes have shown that aspirin can produce regression of existing colorectal adenomas and prevent the formation of new polyps. However, the lowest effective doses, treatment duration, target populations, and the effects on survival are not entirely clear. Although not common serious side effects and in particular gastrointestinal and intracerebral hemorrhage do occur, better selection of individuals who might benefit the most from aspirin use must be carefully performed in order to maximize their risk/benefit ratio. In the era of precision medicine, genetic information, blood and/or urinary biomarkers, could potentially help in tailoring chemopreventive therapeutic strategies, based on aspirin use, while limiting adverse toxic effects. The current review will cover the use of aspirin for the prevention of colorectal adenomas and CRC, potential markers for chemoprevention, and patient stratification.
Keywords: Adenomas, aspirin, cardiovascular disease (CVD), colorectal cancer (CRC), non-steroidal anti-inflammatory drugs (NSAIDs), single nucleotide polymorphisms (SNPs).
Current Pharmaceutical Design
Title:Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Volume: 21 Issue: 35
Author(s): Sarah Kraus, Daniel Sion and Nadir Arber
Affiliation:
Keywords: Adenomas, aspirin, cardiovascular disease (CVD), colorectal cancer (CRC), non-steroidal anti-inflammatory drugs (NSAIDs), single nucleotide polymorphisms (SNPs).
Abstract: Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease. It has one of the strongest cumulative evidence supporting its use in colorectal cancer (CRC) chemoprevention. Epidemiological, clinical, and observational studies have demonstrated that aspirin and non-steroidal antiinflammatory drugs (NSAIDs), including COX-2 inhibitors, can protect against CRC and significantly reduce its incidence. Moreover, prospective randomized controlled trials of colorectal polyp recurrence and in patients with hereditary CRC syndromes have shown that aspirin can produce regression of existing colorectal adenomas and prevent the formation of new polyps. However, the lowest effective doses, treatment duration, target populations, and the effects on survival are not entirely clear. Although not common serious side effects and in particular gastrointestinal and intracerebral hemorrhage do occur, better selection of individuals who might benefit the most from aspirin use must be carefully performed in order to maximize their risk/benefit ratio. In the era of precision medicine, genetic information, blood and/or urinary biomarkers, could potentially help in tailoring chemopreventive therapeutic strategies, based on aspirin use, while limiting adverse toxic effects. The current review will cover the use of aspirin for the prevention of colorectal adenomas and CRC, potential markers for chemoprevention, and patient stratification.
Export Options
About this article
Cite this article as:
Kraus Sarah, Sion Daniel and Arber Nadir, Can We Select Patients for Colorectal Cancer Prevention with Aspirin?, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915111000
DOI https://dx.doi.org/10.2174/1381612821666150915111000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics Glutathione Transferases: Emerging Multidisciplinary Tools in Red and Green Biotechnology
Recent Patents on Biotechnology Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications
Current Cancer Drug Targets The Roles of MicroRNAs in Heart Diseases: A Novel Important Regulator
Current Medicinal Chemistry Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity
Current Medicinal Chemistry Studies on the IC<sub>50</sub> of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors
Letters in Drug Design & Discovery Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma
Current Pharmaceutical Design Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry The Role of LEF/TCF Factors in Neoplastic Transformation
Current Molecular Medicine Synthesis of Metronidazole Derivatives Containing Pyridine Ring and Anticancer Activity
Letters in Organic Chemistry Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery miR-21 and let-7 in the Ras and NF-κB Pathways
MicroRNA Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Nano-Phytosome: A Developing Platform for Herbal Anti-Cancer Agents in Cancer Therapy
Current Drug Targets